J.Jpn. Surg. Soc.
ISSN 1880-1129

[Abstract] [Full Text HTML] [Full Text PDF] （in Japanese / 397KB） [Members Only]

J.Jpn. Surg. Soc.. 118(6): 616-621, 2017

Feature topic

HOW DOES THE DEVELOPMENT OF MOLECULAR-TARGETED THERAPY AFFECT SURGERY IN LUNG CANCER?

1) Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osakasayama, Japan
2) Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA

Suda Kenichi1)2), Mitsudomi Tetsuya1)

Molecular-targeted drugs have become an essential class of agents in the treatment of advanced non-small cell lung cancer (NSCLC). Small-molecule inhibitors that act against driver mutations (e.g., epidermal growth factor receptor [EGFR] mutations or anaplastic lymphoma kinase translocations), antiangiogenic agents, and anti-EGFR monoclonal antibody are currently used or are under development for the treatment of advanced NSCLC patients.
The potential role of molecular-targeted drugs in early-stage NSCLC or in the adjuvant setting after “curative” pulmonary resection has been suggested and is currently being investigated in phase III trials. Molecular-targeted drugs have also increased the role of surgery and surgeons in the treatment of advanced NSCLC. These include neoadjuvant molecular-targeted therapy followed by surgery in locally advanced NSCLC, surgery as a strategy to obtain tissue samples for biomarker analysis, and surgical resection for oligoprogressive lesions during treatment with molecular-targeted drugs. Along with the development of molecular-targeted drugs, the role of surgery and surgeons is expanding.

<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.